The  ||| S:0 E:4 ||| DT
JUPITER  ||| S:4 E:12 ||| NNP
trial ||| S:12 E:17 ||| NN
:  ||| S:17 E:19 ||| :
a  ||| S:19 E:21 ||| DT
new  ||| S:21 E:25 ||| JJ
approach  ||| S:25 E:34 ||| NN
in  ||| S:34 E:37 ||| IN
primary  ||| S:37 E:45 ||| JJ
prevention  ||| S:45 E:56 ||| NN
Current  ||| S:56 E:64 ||| JJ
practice  ||| S:64 E:73 ||| NN
guidelines  ||| S:73 E:84 ||| NNS
recommend  ||| S:84 E:94 ||| VBP
that ||| S:94 E:98 ||| RB
,  ||| S:98 E:100 ||| ,
when  ||| S:100 E:105 ||| WRB
determining  ||| S:105 E:117 ||| VBG
target  ||| S:117 E:124 ||| NN
LDL-cholesterol  ||| S:124 E:140 ||| JJ
levels  ||| S:140 E:147 ||| NNS
in  ||| S:147 E:150 ||| IN
individuals  ||| S:150 E:162 ||| NNS
without  ||| S:162 E:170 ||| IN
cardiovascular  ||| S:170 E:185 ||| JJ
disease  ||| S:185 E:193 ||| NN
and  ||| S:193 E:197 ||| CC
diabetes ||| S:197 E:205 ||| NN
,  ||| S:205 E:207 ||| ,
global  ||| S:207 E:214 ||| JJ
risk  ||| S:214 E:219 ||| NN
estimation  ||| S:219 E:230 ||| RB
be  ||| S:230 E:233 ||| VB
made  ||| S:233 E:238 ||| VBN
taking  ||| S:238 E:245 ||| VBG
into  ||| S:245 E:250 ||| IN
account  ||| S:250 E:258 ||| NN
age ||| S:258 E:261 ||| NN
,  ||| S:261 E:263 ||| ,
sex ||| S:263 E:266 ||| NN
,  ||| S:266 E:268 ||| ,
total  ||| S:268 E:274 ||| JJ
cholesterol  ||| S:274 E:286 ||| NN
level ||| S:286 E:291 ||| NN
,  ||| S:291 E:293 ||| ,
HDL-cholesterol  ||| S:293 E:309 ||| JJ
level ||| S:309 E:314 ||| NN
,  ||| S:314 E:316 ||| ,
smoking  ||| S:316 E:324 ||| NN
status ||| S:324 E:330 ||| NN
,  ||| S:330 E:332 ||| ,
and  ||| S:332 E:336 ||| CC
systolic  ||| S:336 E:345 ||| JJ
blood  ||| S:345 E:351 ||| NN
pressure ||| S:351 E:359 ||| NN
.  ||| S:359 E:361 ||| .
Based  ||| S:361 E:367 ||| VBN
on  ||| S:367 E:370 ||| IN
this  ||| S:370 E:375 ||| DT
assessment ||| S:375 E:385 ||| NN
,  ||| S:385 E:387 ||| ,
target  ||| S:387 E:394 ||| NN
LDL-cholesterol  ||| S:394 E:410 ||| JJ
levels  ||| S:410 E:417 ||| NNS
have  ||| S:417 E:422 ||| VBP
been  ||| S:422 E:427 ||| VBN
set  ||| S:427 E:431 ||| VBN
as  ||| S:431 E:434 ||| IN
< ||| S:434 E:435 ||| SYM
100  ||| S:435 E:439 ||| CD
mg ||| S:439 E:441 ||| CD
/ ||| S:441 E:442 ||| CD
dL ||| S:442 E:444 ||| NN
,  ||| S:444 E:446 ||| ,
< ||| S:446 E:447 ||| SYM
130  ||| S:447 E:451 ||| CD
mg ||| S:451 E:453 ||| CD
/ ||| S:453 E:454 ||| CD
dL ||| S:454 E:456 ||| NN
,  ||| S:456 E:458 ||| ,
and  ||| S:458 E:462 ||| CC
< ||| S:462 E:463 ||| SYM
160  ||| S:463 E:467 ||| CD
mg ||| S:467 E:469 ||| CD
/ ||| S:469 E:470 ||| CD
dL  ||| S:470 E:473 ||| NN
for  ||| S:473 E:477 ||| IN
high- ||| S:477 E:482 ||| NNP
,  ||| S:482 E:484 ||| ,
intermediate- ||| S:484 E:497 ||| NNP
,  ||| S:497 E:499 ||| ,
and  ||| S:499 E:503 ||| CC
low-risk  ||| S:503 E:512 ||| JJ
individuals ||| S:512 E:523 ||| NNS
,  ||| S:523 E:525 ||| ,
respectively ||| S:525 E:537 ||| RB
.  ||| S:537 E:539 ||| .
The  ||| S:539 E:543 ||| DT
most  ||| S:543 E:548 ||| RBS
important  ||| S:548 E:558 ||| JJ
rationale  ||| S:558 E:568 ||| NN
for  ||| S:568 E:572 ||| IN
this  ||| S:572 E:577 ||| DT
approach  ||| S:577 E:586 ||| NN
is  ||| S:586 E:589 ||| VBZ
to  ||| S:589 E:592 ||| TO
implement  ||| S:592 E:602 ||| VB
a  ||| S:602 E:604 ||| DT
cost-effective  ||| S:604 E:619 ||| JJ
treatment  ||| S:619 E:629 ||| NN
strategy ||| S:629 E:637 ||| NN
,  ||| S:637 E:639 ||| ,
giving  ||| S:639 E:646 ||| VBG
special  ||| S:646 E:654 ||| JJ
attention  ||| S:654 E:664 ||| NN
to  ||| S:664 E:667 ||| TO
high-risk  ||| S:667 E:677 ||| JJ
individuals  ||| S:677 E:689 ||| NNS
when  ||| S:689 E:694 ||| WRB
allocating  ||| S:694 E:705 ||| VBG
available  ||| S:705 E:715 ||| JJ
sources ||| S:715 E:722 ||| NNS
.  ||| S:722 E:724 ||| .
Recent  ||| S:724 E:731 ||| JJ
data  ||| S:731 E:736 ||| NNS
suggest  ||| S:736 E:744 ||| VBP
that  ||| S:744 E:749 ||| IN
increased  ||| S:749 E:759 ||| JJ
levels  ||| S:759 E:766 ||| NNS
of  ||| S:766 E:769 ||| IN
high  ||| S:769 E:774 ||| JJ
sensitive  ||| S:774 E:784 ||| JJ
C-reactive  ||| S:784 E:795 ||| JJ
protein  ||| S:795 E:803 ||| NN
( ||| S:803 E:804 ||| -LRB-
hs-CRP ||| S:804 E:810 ||| NNP
)  ||| S:810 E:812 ||| -RRB-
are  ||| S:812 E:816 ||| VBP
associated  ||| S:816 E:827 ||| VBN
with  ||| S:827 E:832 ||| IN
increased  ||| S:832 E:842 ||| JJ
risk  ||| S:842 E:847 ||| NN
for  ||| S:847 E:851 ||| IN
cardiovascular  ||| S:851 E:866 ||| JJ
events ||| S:866 E:872 ||| NNS
,  ||| S:872 E:874 ||| ,
independent  ||| S:874 E:886 ||| JJ
of  ||| S:886 E:889 ||| IN
other  ||| S:889 E:895 ||| JJ
risk  ||| S:895 E:900 ||| NN
parameters ||| S:900 E:910 ||| NNS
.  ||| S:910 E:912 ||| .
Most  ||| S:912 E:917 ||| RBS
recently ||| S:917 E:925 ||| RB
,  ||| S:925 E:927 ||| ,
the  ||| S:927 E:931 ||| DT
JUPITER  ||| S:931 E:939 ||| NNP
trial  ||| S:939 E:945 ||| NN
demonstrated  ||| S:945 E:958 ||| VBN
that  ||| S:958 E:963 ||| IN
rosuvastatin  ||| S:963 E:976 ||| CD
20  ||| S:976 E:979 ||| CD
mg ||| S:979 E:981 ||| CD
/ ||| S:981 E:982 ||| CD
day  ||| S:982 E:986 ||| NN
significantly  ||| S:986 E:1000 ||| RB
lowered  ||| S:1000 E:1008 ||| VBD
cardiovascular  ||| S:1008 E:1023 ||| JJ
mortality  ||| S:1023 E:1033 ||| NN
and  ||| S:1033 E:1037 ||| CC
all-cause  ||| S:1037 E:1047 ||| JJ
mortality  ||| S:1047 E:1057 ||| NN
in  ||| S:1057 E:1060 ||| IN
low-  ||| S:1060 E:1065 ||| JJ
or  ||| S:1065 E:1068 ||| CC
intermediate-risk  ||| S:1068 E:1086 ||| JJ
patients  ||| S:1086 E:1095 ||| NNS
whose  ||| S:1095 E:1101 ||| WP$
LDL-cholesterol  ||| S:1101 E:1117 ||| JJ
levels  ||| S:1117 E:1124 ||| NNS
were  ||| S:1124 E:1129 ||| VBD
< ||| S:1129 E:1130 ||| SYM
130  ||| S:1130 E:1134 ||| CD
mg ||| S:1134 E:1136 ||| CD
/ ||| S:1136 E:1137 ||| CD
dL  ||| S:1137 E:1140 ||| NNS
( ||| S:1140 E:1141 ||| -LRB-
median  ||| S:1141 E:1148 ||| JJ
108  ||| S:1148 E:1152 ||| CD
mg ||| S:1152 E:1154 ||| CD
/ ||| S:1154 E:1155 ||| CD
dL ||| S:1155 E:1157 ||| NN
)  ||| S:1157 E:1159 ||| -RRB-
and  ||| S:1159 E:1163 ||| CC
hs-CRP  ||| S:1163 E:1170 ||| JJ
levels  ||| S:1170 E:1177 ||| NNS
were  ||| S:1177 E:1182 ||| VBD
= ||| S:1182 E:1183 ||| CD
/ ||| S:1183 E:1184 ||| CD
> ||| S:1184 E:1185 ||| CD
2  ||| S:1185 E:1187 ||| CD
mg ||| S:1187 E:1189 ||| CD
/ ||| S:1189 E:1190 ||| CD
L ||| S:1190 E:1191 ||| NNP
.  ||| S:1191 E:1193 ||| .
As  ||| S:1193 E:1196 ||| IN
the  ||| S:1196 E:1200 ||| DT
current  ||| S:1200 E:1208 ||| JJ
guidelines  ||| S:1208 E:1219 ||| NNS
do  ||| S:1219 E:1222 ||| VBP
not  ||| S:1222 E:1226 ||| RB
recommend  ||| S:1226 E:1236 ||| VB
statin  ||| S:1236 E:1243 ||| JJ
therapy  ||| S:1243 E:1251 ||| NN
for  ||| S:1251 E:1255 ||| IN
this  ||| S:1255 E:1260 ||| DT
patient  ||| S:1260 E:1268 ||| JJ
group ||| S:1268 E:1273 ||| NN
,  ||| S:1273 E:1275 ||| ,
these  ||| S:1275 E:1281 ||| DT
results  ||| S:1281 E:1289 ||| NNS
have  ||| S:1289 E:1294 ||| VBP
caused  ||| S:1294 E:1301 ||| VBN
a  ||| S:1301 E:1303 ||| DT
widespread  ||| S:1303 E:1314 ||| JJ
interest ||| S:1314 E:1322 ||| NN
,  ||| S:1322 E:1324 ||| ,
giving  ||| S:1324 E:1331 ||| VBG
rise  ||| S:1331 E:1336 ||| NN
to  ||| S:1336 E:1339 ||| TO
arguments  ||| S:1339 E:1349 ||| NNS
about  ||| S:1349 E:1355 ||| IN
the  ||| S:1355 E:1359 ||| DT
effectiveness  ||| S:1359 E:1373 ||| NN
of  ||| S:1373 E:1376 ||| IN
primary  ||| S:1376 E:1384 ||| JJ
prevention  ||| S:1384 E:1395 ||| NN
recommendations  ||| S:1395 E:1411 ||| NNS
of  ||| S:1411 E:1414 ||| IN
the  ||| S:1414 E:1418 ||| DT
guidelines ||| S:1418 E:1428 ||| NNS
.  ||| S:1428 E:1430 ||| .
This  ||| S:1430 E:1435 ||| DT
review  ||| S:1435 E:1442 ||| NN
aims  ||| S:1442 E:1447 ||| VBZ
to  ||| S:1447 E:1450 ||| TO
discuss  ||| S:1450 E:1458 ||| VB
the  ||| S:1458 E:1462 ||| DT
results  ||| S:1462 E:1470 ||| NNS
and  ||| S:1470 E:1474 ||| CC
implications  ||| S:1474 E:1487 ||| NNS
of  ||| S:1487 E:1490 ||| IN
the  ||| S:1490 E:1494 ||| DT
JUPITER  ||| S:1494 E:1502 ||| NNP
trial ||| S:1502 E:1507 ||| NN
.  ||| S:1507 E:1509 ||| .
